drugset
drugset / Trial / NCT04045769

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

NCT04045769 ↗

Phase 1 Completed 52 enrolled Zydus Therapeutics Inc.
RandomizedCrossoverQuadruple-blindOther

Summary

A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Timeline

Start
2019-08-19
Primary completion
2019-11-27
Completion
2019-12-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Saroglitazar Small molecule 4 mg Oral
Subject Saroglitazar Small molecule 20 mg Oral

Indications

No indication recorded.